Juncture Wealth Strategies’s Corcept Therapeutics CORT Stock Holding History

Juncture Wealth Strategies’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,532	Closed	-$262K	–	136
2025 Q4	$262K	Buy	7,532 +140	+2%	+$11K	0.09%	116
2025 Q3	$614K	Buy	7,392 +1,279	+21%	+$92.6K	0.21%	63
2025 Q2	$449K	Buy	6,113 +575	+10%	+$41.7K	0.16%	77
2025 Q1	$633K	Buy	+5,538	New	+$337K	0.25%	67
2021 Q1	–	Sell	-13,330	Closed	-$349K	–	107
2020 Q4	$349K	Sell	13,330 -11,061	-45%	-$233K	0.22%	84
2020 Q3	$425K	Buy	24,391 +1,810	+8%	+$28.8K	0.29%	75
2020 Q2	$380K	Buy	+22,581	New	+$317K	0.29%	78

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Juncture Wealth Strategies's CORT Position: Q1 2026 in Review

Juncture Wealth Strategies sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 7,532 shares — an estimated $262K sold.

Juncture Wealth Strategies first reported a position in CORT in Q2 2020 and held it in 7 quarters. The position peaked at $633K in Q1 2025. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

Juncture Wealth Strategies reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
Juncture Wealth Strategies sold 7,532 Corcept Therapeutics shares in Q1 2026, an estimated $262K.
Juncture Wealth Strategies first reported a position in Corcept Therapeutics in Q2 2020 and held it in 7 quarters.
Juncture Wealth Strategies's Corcept Therapeutics position peaked at $633K in Q1 2025.
352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Juncture Wealth Strategies's 13F filing for Q1 2026, filed 15 Apr 2026.